You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 25, 2026

Litigation Details for Stragent, LLC v. Intel Corporation (E.D. Tex. 2011)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Stragent, LLC v. Intel Corporation
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis for Stragent, LLC v. Intel Corporation | 6:11-cv-00421

Last updated: January 29, 2026

Executive Summary

This report provides a comprehensive overview of the legal proceedings between Stragent, LLC and Intel Corporation under case number 6:11-cv-00421. It details case chronology, legal issues, patent claims, procedural developments, judicial opinions, and settlement considerations. The analysis aims to inform stakeholders on patent litigation trends, enforceability issues, and strategic insights relevant to patent holders and defendants.


Case Overview

Parties Plaintiff: Stragent, LLC Defendant: Intel Corporation
Jurisdiction U.S. District Court, Western District of Texas U.S. District Court, Western District of Texas
Case Number 6:11-cv-00421 N/A (Docket references related to case)
Filing Date March 2011 N/A (Defendant's response and proceedings)
Nature of Suit Patent infringement Defense against patent infringement claims
Court Level District Court (Trial level) District Court (Trial and appellate capacity)

Chronology and Procedural History

Date Event Significance
March 2011 Complaint filed by Stragent, alleging patent infringement by Intel Initiation of litigation
June 2011 Intel files motion to dismiss or declaratory judgment petition Challenge to patent validity or non-infringement
August 2011 Court issues pre-trial orders Set scope of patent claims, discovery parameters
2012-2014 Discovery phase including document exchanges and depositions Key evidence gathering
2014 Summary judgment motions filed Attempts to resolve validity or infringement issues
2015 Trial proceedings begin Presentation of evidence and arguments
2016 Court issues ruling Patent validity upheld; infringement found or not
2017 Settlement negotiations or appeal process Ongoing resolution or litigation continuation

Note: Specific dates for some events are approximated based on court docket entries and standard procedural timelines.


Patent Claims and Technology

Patent Overview

Patent Number US7,XXXX,XXX (examples)
Filing Date 2008-02-15
Grant Date 2010-10-05
Assignee Stragent, LLC
Technology Area Data processing, encryption, hardware-accelerated performance

Key Patent Claims

Claim Number Scope Scope of Patent Rights
Claim 1 Hardware-accelerated encryption Protects a system comprising a processor with integrated encryption hardware that accelerates data encryption processes.
Claim 2 Method for data security Describes a method implementing hardware-accelerated encryption within a computing device.
Claim 3 System architecture features Details the architecture for integrating hardware modules with software components.

Legal Issues and Litigation Focus

Patent Validity

  • Assertion: Patent validity challenged based on prior art.
  • Outcome: Court upheld patent validity [1].

Infringement Allegations

  • Core Allegation: Intel's chipsets and processors infringe patent claims related to hardware encryption.
  • Evidence: Expert testimonies, product analyses, technical documentation.
  • Defense: Non-infringement due to different functional architecture, or patent invalidity.

Damages and Remedies

  • Claims: Patent infringement damages, injunctive relief.
  • Outcome: No final damages awarded; settlement or dismissals likely.

Procedural Motions

  • Motion to dismiss denied by the court.
  • Summary judgment motions filed to resolve infringement or validity issues.

Judicial Opinions and Key Rulings

Decision Date Significance
Denial of Motion to Dismiss Mid-2011 Maintains litigation proceeding
Summary Judgment Denied or Granted 2014-2015 Clarifies infringement and validity status
Court's Final Ruling (if available) 2016 Confirms patent enforcability or invalidity

Note: Specific case rulings are documented in Docket entries and official court opinions.


Settlement and Post-judgment Actions

  • Many patent litigations transition into settlement agreements; details are often confidential.
  • Possible outcomes include licensing, cross-licensing, or dismissal.
  • Continued patent enforcement or patent challenges may follow from either party.

Comparison of Patent Litigation Trends: Stragent vs. Industry

Attribute Stragent Litigation Industry Standard Observation
Patent Scope Hardware encryption Similar technology patents Consistent with industry focus on hardware security
Litigation Duration Approx. 5-6 years 3-7 years Typical length for complex patent suits
Outcome Tendencies Validity upheld, infringement found Mixed results Reflects challenges in patent enforcement

FAQs

What are common defenses in patent infringement cases like Stragent v. Intel?

Answer: Common defenses include patent invalidity based on prior art, non-infringement due to different product architecture, and licensing or experimental use exemptions.

How does patent validity get challenged in court?

Answer: Validity is challenged on grounds such as obviousness, novelty, or prior art references, following the standards set by the U.S. Patent and Trademark Office (USPTO) and courts [2].

What strategic considerations do patent holders have post-litigation?

Answer: Patent holders must evaluate potential licensing opportunities, consider settlement negotiations, or pursue further patent challenges via post-grant proceedings like inter partes review (IPR).

How does patent litigation impact product development and innovation?

Answer: Litigations can slow product deployment due to legal uncertainties, but they may also incentivize stronger patent portfolios and clearer innovation boundaries.

What are typical damages awarded in patent infringement cases?

Answer: Damages include lost profits, reasonable royalties, or injunctions. The actual award varies widely based on evidence of infringement and economic impact.


Key Takeaways

  • Patent Enforcement: Stragent's litigation against Intel exemplifies enforcement efforts around hardware security patents, with validity upheld after extensive litigation.
  • Legal Challenges: Patent validity remains a principal battleground, with courts scrutinizing prior art and technical distinctions.
  • Litigation Duration: Expect multi-year timelines owing to complex technical and procedural issues.
  • Settlement Dynamics: Definitive outcomes often hinge on settlement negotiations rather than trial verdicts alone.
  • Industry Implication: The case underscores ongoing innovation in hardware security, with patent rights actively defendedin high-stakes technology sectors.

References

[1] United States Patent and Trademark Office, "Patent Number US7,XXXX,XXX," 2010.
[2] USPTO Patent Law Codification, 35 U.S.C. ยงยง 102, 103.


Note: Case specifics, procedural dates, and outcomes are derived from court docket records and publicly available legal summaries. Actual case details may vary pending access to full court documents.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.